The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01947582 |
Recruitment Status :
Completed
First Posted : September 20, 2013
Results First Posted : June 1, 2015
Last Update Posted : March 7, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Sclerosis | Device: Ankle foot orthosis | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS) |
Study Start Date : | October 2013 |
Actual Primary Completion Date : | December 2014 |
Actual Study Completion Date : | December 2014 |

Arm | Intervention/treatment |
---|---|
Application of ankle foot orthosis
All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
|
Device: Ankle foot orthosis
The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated. |
- Change in Walking Distance During 6-Minute Walk Test [ Time Frame: Assessed at visit 2 (week 1) and week 24 ]Each participant walks at a self-selected velocity on level surfaces for 6 minutes. They will be allowed to use assistive devices if necessary. They will be asked to rate their level of exertion upon completion of walking on the rate of perceived exertion scale.
- Change in Impact of MS on Fatigue Using the 12-Item Walk Scale [ Time Frame: Assessed at visit 2 (week 1) and week 24 ]The 12-Item Walk Scale is a paper and pencil test that asks persons with MS to rate their level of fatigue when doing functional tasks. The maximum possible score is 60 points and the lowest possible score is 12. Higher scores indicate a greater impact on walking than lower scores.
- Change in Step Length Using the GAITRite Computerized Gait Analysis System [ Time Frame: Assessed at visit 2 (week 1) and week 24 ]Participants will be asked to walk on a 12-16 foot long vinyl pad placed on the floor.
- Number of Persons With Change in Muscle Activity Using Surface Electromyography (EMG) [ Time Frame: Assessed at visit 2 (week 1) and week 24 ]Surface EMG is done on key muscles in the lower extremity (quadriceps, anterior tibialis, gastrocnemius, soleus) during computerized gait assessment. Changes in amplitude of muscle activity or timing of muscle activity would indicate, for example, increases in strength or changes in timing of muscles which might indicate motor learning as a result of wearing the ankle foot orthosis.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Individuals with a primary diagnosis of multiple sclerosis
- Individuals who are able to maintain a walking velocity of 30 cm/sec for at least 2 minutes independently or with the use of a single tip assistive device.
- Could have current or past history of single or bilateral AFO use, including neuroprostheses
- Evidence of weakness in plantarflexors
Exclusion Criteria:
- The presence of co-morbidities (neuromuscular or musculoskeletal) that would negatively impact gait training
- Individuals with BMI with >/= 40kg/m2
- Individuals with range of motion deficit in the ankle limiting passive range of motion to neutral dorsiflexion
- Individuals that plan to begin the use of Ampyra during the course of the study
- Individuals for whom the cost of an orthosis would represent a financial burden
- Individuals who are receiving concurrent physical therapy services elsewhere
- MSNQ of >22

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01947582
United States, Texas | |
UT Southwestern Medical Center School of Health Professions | |
Dallas, Texas, United States, 75223 |
Principal Investigator: | Karen J McCain, PT, DPT, NCS | University of Texas Southwestern Medical Center |
Responsible Party: | Karen McCain, Associate Professor, School of Health Professions, University of Texas Southwestern Medical Center |
ClinicalTrials.gov Identifier: | NCT01947582 |
Other Study ID Numbers: |
MS Bracing |
First Posted: | September 20, 2013 Key Record Dates |
Results First Posted: | June 1, 2015 |
Last Update Posted: | March 7, 2016 |
Last Verified: | February 2016 |
multiple sclerosis gait ankle foot orthosis (AFO) |
Multiple Sclerosis Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |
Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases |